AG
EIGR

Algert Global’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Algert Global’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,103
Closed -$221K – 1150
2021
Q3 		$221K Sell
1,103
-58
-5% -$13.8K 0.03% 873
2021
Q2 		$297K Sell
1,161
-147
-11% -$36.7K 0.1% 289
2021
Q1 		$347K Sell
1,308
-1,929
-60% -$608K 0.11% 278
2020
Q4 		$1.19M Sell
3,237
-16
-0.5% -$4.59K 0.34% 109
2020
Q3 		$794K Buy
3,253
+2
+0.1% +$622 0.25% 145
2020
Q2 		$936K Sell
3,251
-224
-6% -$66K 0.32% 115
2020
Q1 		$709K Buy
3,475
+1,712
+97% +$546K 0.3% 126
2019
Q4 		$788K Buy
1,763
+199
+13% +$70.6K 0.24% 148
2019
Q3 		$481K Buy
1,564
+605
+63% +$197K 0.18% 158
2019
Q2 		$305K Buy
959
+371
+63% +$128K 0.11% 223
2019
Q1 		$247K Sell
588
-1,347
-70% -$541K 0.14% 221
2018
Q4 		$590K Sell
1,935
-329
-15% -$106K 0.16% 199
2018
Q3 		$815K Buy
2,264
+1,507
+199% +$515K 0.18% 195
2018
Q2 		$277K Buy
+757
New +$270K 0.06% 293

Other funds holding EIGR

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Algert Global's EIGR Position: Q4 2021 in Review

Algert Global sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q4 2021, closing a stake of 1,103 shares — an estimated $221K sold.

Algert Global first reported a position in EIGR in Q2 2018 and held it in 14 quarters. The position peaked at $1.19M in Q4 2020. 85 funds tracked by Wall St. Rank hold EIGR as of Q4 2021.

  • Algert Global reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Algert Global sold 1,103 Eiger BioPharmaceuticals, Inc. shares in Q4 2021, an estimated $221K.
  • Algert Global first reported a position in Eiger BioPharmaceuticals, Inc. in Q2 2018 and held it in 14 quarters.
  • Algert Global's Eiger BioPharmaceuticals, Inc. position peaked at $1.19M in Q4 2020.
  • 85 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q4 2021.

Based on Algert Global's 13F filing for Q4 2021, filed 14 Feb 2022.